4DMT to Participate in Upcoming Investor Conference
May 07 2024 - 8:00AM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company),
a leading clinical-stage genetic medicines company focused on
unlocking the full potential of genetic medicines to treat large
market diseases, today announced that management will
participate in a fireside chat at an upcoming investor conference
in May. Members of the management team will also be available for
one-on-one meetings.
Bank of America Health Care Conference 2024
Presentation Date: |
Tuesday, May 14, 2024 |
Presentation Time: |
3:40 p.m. PT / 6:40 p.m. ET |
Webcast Link: |
Webcast |
Archived copies of the webcasts will be available for up to one
year by visiting the “Investors” section of the 4DMT website at
https://ir.4dmoleculartherapeutics.com/events.
About 4DMT 4DMT is a leading
clinical-stage genetic medicines company focused on unlocking the
full potential of genetic medicines to treat large market diseases
in ophthalmology and pulmonology. 4DMT’s proprietary invention
platform, Therapeutic Vector Evolution, combines the power of the
Nobel Prize-winning technology, directed evolution, with
approximately one billion synthetic AAV capsid-derived sequences to
invent customized and evolved vectors for use in our wholly owned
and partnered product candidates. Our product design, development,
and manufacturing engine help us efficiently create and advance our
diverse product pipeline with the goal of revolutionizing medicine
with potential curative therapies for millions of patients.
Currently, 4DMT is advancing five clinical-stage and two
preclinical product candidates, each tailored to address rare and
large market diseases in ophthalmology, pulmonology, and
cardiology. In addition, 4DMT is also advancing programs in CNS
through a gene editing partnership. 4D Molecular Therapeutics™,
4DMT®, 4D®, Therapeutic Vector Evolution™, and the 4DMT logo are
trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the FDA
or any other regulatory authority. No representation is made as to
the safety or effectiveness of our product candidates for the
therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors:
Julian PeiHead of Investor Relations and Corporate
CommunicationsInvestor.Relations@4DMT.com
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From Apr 2024 to May 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From May 2023 to May 2024